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Lung cancer is the leading cause of cancer death worldwide;its 5-year survival rate is only 15%. The therapy for this
disease is improving with the advent of new targeted thera-
pies, agents that are potentially more effective and less toxic.
This has resulted from a better understanding of the molec-
ular pathogenesis of this disease with the advent of new drugs
or combinations for this disease. In February 2007, a 3-day
conference in Santa Monica was sponsored by the Interna-
tional Association for the Study of Lung Cancer, which brought
together 50 world experts in the treatment of this disease.
Vascular Endothelial Growth Factor Inhibitors
Lawrence Einhorn, MD
Vascular endothelial growth factor (VEGF) is one of
the most important growth factors that regulate angiogenesis.
Bevacizumab has proven efficacy in colorectal cancer, non-
small cell lung cancer (NSCLC), renal cell carcinoma, and
other tumor types. It is the only molecularly targeted agent
proven to improve survival when combined with chemother-
apy as first-line therapy in NSCLC. Molecular markers such
as the intercellular adhesion molecule may be useful as a
biomarker.
These agents have common toxic effects, especially
hypertension, proteinuria, while less frequent toxicities such
as thromboses, and hemoptysis are occasionally fatal. My-
elosuppression and febrile neutropenic are more frequent
when combined with chemotherapy compared with chemo-
therapy alone. A new toxicity, tracheo-esophageal fistula, has
recently been observed with chemotherapy bevacizumab in
a SCLC trial.
This review will cover several new agents that target
VEGF and are showing promise in NSCLC.
AZD 2171—This is a small-molecule tyrosine kinase
inhibitor (TKI) selective for all VEGF receptors. A phase I
study combined AZD 2171 with carboplatin  paclitaxel
(CP) reported 10 objective responses among 20 patients. A
45-mg dose has been chosen for subsequent phase II/III
studies in NSCLC. This dose was reduced to 30 mg in a
subsequent phase II-III study with carboplatin and paclitaxel
being conducted by the Canadian NCI.
Sorafenib—This agent has been approved for clear cell
renal cell carcinoma, and it has promising activity in previ-
ously treated NSCLC. Phase III studies are under way,
including a 900-patient trial of CP / sorafenib (400 mg
bid) and a similar phase III trial with cisplatin gemcitabine.
This agent is also being evaluated as third-line or later
therapy with randomization to continue or stop therapy after
stable disease or objective response. Finally, it will be eval-
uated with chemoradiotherapy in locally advanced NSCLC.
Sunitinib—This agent, like sorafenib, is approved for
renal cell carcinoma and has activity in NSCLC (with objec-
tive responses in 7 of 63 advanced NSCLC patients [11%]
objective responses and a 44% stable disease rate with dosage
of 50 mg/d for 28 days every 6 weeks). The drug is being
studied combined with various chemotherapy regimens or as
maintenance therapy in both SCLC and NSCLC.
ZD 6474 (Vandetanib)—This is a dual VEGF/epider-
mal growth factor receptor (EGFR) inhibitor. Data previously
presented at The American Society of Clinical Oncology
Meeting compared this agent with gefitinib and found that
*Indiana Cancer Pavilion, Indianapolis, Indiana; †Rush Medical College, Chi-
cago, Illinois; ‡University of Colorado Cancer Center, Aurora, Colorado;
§University of Colorado Health Science Center, Aurora, Colorado; Vander-
bilt University Cancer Center, Nashville, Tennessee; ¶University of Texas,
Southwestern Medical Center, Dallas, Texas; University of California, Los
Angeles, Los Angeles, California; **University of California Davis Cancer
Center, Sacramento, California; ††Anshutz Cancer Pavilion, Aurora, Colo-
rado; ‡‡Washington University of Oncology, St. Louis, Missouri; §§Vanderbilt
Ingram Cancer Center, Nashville, Tennessee; University of Texas Southwest-
ern Medical Center, Dallas, Texas; ¶¶University of Torino, S. Luigi Hospital,
Orbassano, Torino, Italy; ##Swedish Cancer Institute, Seattle, Washington;
***The University of Texas, M.D. Anderson Cancer Center, Houston, Texas.
Editors: P. A. Bunn, Jr., D. H. Johnson, R. S. Herbst.
Address for correspondence: Roy S. Herbst, M.D., Ph.D., Professor of Medicine,
Chief, Section of Thoracic Medical Oncology, Co-Chairman, Phase I Work-
ing Group, Department of Thoracic/Head and Neck Medical Oncology,
Department of Cancer Biology, The University of Texas, M.D. Anderson
Cancer Center, 1515 Holcombe Blvd., Unit 432, Houston, TX 77030-4009.
E-mail: rherbst@mdanderson.org
Drs. Bunn Jr. and Johnson acted as meeting chairman and manuscript editors.
Copyright © 2008 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/08/0305-0545
Journal of Thoracic Oncology • Volume 3, Number 5, May 2008 545
progression-free survival favored vandetanib 11 versus 8
weeks. ZD 6474 studied combined with CP in the first line
setting as second-line therapy combined with docetaxel and
in a separate study, with pemetrexed.
BIBF 1120—This agent has demonstrated activity in
early phase I studies in renal and colorectal cancer and is
being studied alone and combined with CP in patients with
advanced NSCLC. Patients with controlled brain metastases
and squamous histology are eligible for these studies.
VEGF Trap—VEGF Trap is a fusion protein of key
domains from VEGF receptors 1 and 2. Activity has been
observed in heavily pretreated patients with NSCLC. This
agent is synergistic with several cytolytic drugs and is being
studied with Docetaxel in advanced NSCLC.
Thalidomide—This older agent has antiangiogenic ac-
tivity. An ECOG study evaluated thalidomide combined with
chemoradiotherapy in locally advanced NSCLC. There is
evidence of benefit in a study from France when used as
maintenance therapy in SCLC. A larger study in SCLC
randomly allocates patients to receive or not receive mainte-
nance thalidomide after platinum  etoposide in SCLC.
Newer agents with better anti-inflammatory and immuno-
modulatory qualities, such as pomalidomide, are also being
studied in lung cancer. Phase III trials are in progress in both
NSCLC and SCLC.
ABT 869—This is a multitargeted TKI that has dem-
onstrated activity in previously treated patients with NSCLC.
Other agents discussed in this session included the
small molecule VEGFR TKIs AMG 706, pazapanib, AG
013736 (axitinib), and the anti-VEGFR not monoclonal
antibody IMC 1121B.
EGFR Biomarkers and EGFR Selection –
John Minna, David Gandara
Bruce Johnson, MD, reported that the Cancer and
Leukemia Group B (CALGB) is conducting an EGFR bi-
omarker trial to determine the role of EGFR immunohisto-
chemistry (IHC), Flourescence in-situ hybridization (FISH),
and mutation analysis in predicting efficacy of erlotinib
treatment, including objective response time to disease pro-
gression and development of toxicity. CALGB 30406 ran-
domly allocated patients with IIB/IV chemo-naive lung ade-
nocarcinoma to erlotinib or erlotinib  CP and adjusted for
light smoking or never smoking status with mandatory tissue
acquisition. IPASS (centers in East and Southeast Asia) are
comparing gefitinib 250 mg/d followed at progression by CP
versus CP alone in a randomized trial of patients with III,
IIB/IV lung adenocarcinoma with no prior therapy with
exploratory biomarker analysis. A prospective Spanish trial
randomly allocates patients with untreated NSCLC III and
IIIB/IV with EGFR mutations to erlotinib 150 mg/d versus
cisplatin  taxane or gemcitabine.
Fred Hirsch, MD, PhD, reported that high EGFR gene
copy number assessed by FISH in several patient cohorts
(SWOG/Italian, ISEL, BR21) predicted beneficial effects of
erlotinib, gefitinib, and cetuximab. Using EGFR FISH and
IHC, an analysis by TRIBUTE indicated a nonfavorable
effect of EGFR TKIs given concomitantly with chemother-
apy and EGFR FISH negative IHC negative (30% of patients)
resulted in no benefit seen from EGFR TKI therapy. A trial of
erlotinib as a single agent or intercalated with chemotherapy
in chemo-naive IIB/IV NSCLC that are EGFR IHC positive
or FISH positive is ongoing by Bunn/Hirsch. RADIANT is a
erlotinib adjuvant trial of patients with completely resected
stage IB-IIIA EGFR NSCLC who then receive (optional)
four cycles of standard platinum-based chemotherapy fol-
lowed by random allocation to placebo or erlotinib treat-
ment (150 mg/p.o. daily for 2 years). This trial will be
chaired by Karen Kelly.
Ming-Sound Tsao, MD, presented an update on BR.21.
There were 731 patients entered into the study, and 201 had
successful EGFR mutation analysis (mutations were found in
24 patients [12%]). Responses to erlotinib therapy were 30%
in the mutation-positive tumors and 7.6% in tumors without
EGFR mutations (p  0.05). With more sensitive EGFR
mutation techniques in 204 patients, mutations were found in
34 (17%) of patients and the response rate 26.7% in mutation-
positive tumors and 6.9% in mutation-negative tumors (p 
0.035). The survival benefit from erlotinib therapy was
slightly but not significantly greater for patients with mutant
tumors than for those with nonmutant tumors. An increased
gene copy number of EGFR as assessed by FISH showed a
greater differential benefit than the mutation status.
David Carbone, MD, reported that serum proteomic
biomarkers predict a clinical benefit of EGFR TKIs in studies
of pretreatment peripheral blood. These studies had indepen-
dent analysis at Vanderbilt and the University of Colorado
Cancer Center and involved studies of patient serum speci-
mens from Japan and Italy. They were also validated in an
ECOG cohort of advanced NSCLC with first-line erlotinib.
They provide cross-institution validation and predict survival
times from “good” and “poor” prognosis serum proteomic
signatures. These lead into the NCI-sponsored Lung Cancer
SPECs trial of erlotinib, which is evaluating protein and
mRNA expression, and FISH and IHC tumor profiles and
proteomics serum profiles.
Adi Gazdar, MD, reported that KRAS mutations are
present in NSCLC but never in SCLC and are strongly
associated with smoking. The mutational spectrum is limited
mainly to G:T transversions in codons 12 and 13. Gender
differences in prevalence exist. Independent factors associ-
ated with EGFR and KRAS mutations in lung cancer are ever
smoking, male sex, ethnicity other than East Asian, poor
response to EGFR TKIs, and a high DNA tumor suppressor
gene methylation index. KRAS mutations target different
subpopulations than EGFR and demonstrate mutual exclu-
sion. KRAS mutation is a potent negative factor for survival
indicating different pathways to lung adenocarcinoma in ever
and never smokers resulting from activation of these genes.
Epithelial to Mesenchymal Transition in NSCLC
and Derivation of Rationale Targeted Therapy
John Haley, PhD (OSI Pharmaceuticals), presented data
on the role of the epithelial to mesenchymal transition (EMT)
in determination of sensitivity to EGFR inhibitors. Both
erlotinib-sensitive and erlotinib-insensitive NSCLC express
EGFR. Erlotinib-sensitive NSCLC also expresses ERBB3
and ECAD, and signaling through the EGFR pathway ap-
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pears dependent on autocrine production of ligand. Erlotinib-
sensitive NSCLC lines express epithelial markers Ecadherin
(ECAD, gamma catenin), whereas erlotinib-insensitive NSCLC
lines express mesenchymal markers (vimentin, fibronectin, Zeb-1).
Epithelial cell EGFR dependence is linked to cell-cell junc-
tions, ECAD expression, and cell polarity. ER3 transcription
is frequently attenuated through EMT and acts as a connector
of EGFR-Akt Her3 acts as a key mediator of Akt, and
erlotinib is capable of inhibiting Akt activity only in sensitive
cell lines and this is independent of inhibition of EGFR
phosphorylation. In an analysis of TRIBUTE data, ECAD
tumor-positive patients had a longer time to progression with
erlotinib  chemotherapy than with chemotherapy alone.
Lung cancer cells that have undergone EMT are a key source
of cancer recurrence, as has been demonstrated in ERBB2
transgenic mouse models of cancer that show tumor regres-
sion when ERBB2 expression is removed but recurrence
without ERBB2 expression accompanied by tumors with
EMT. Thus, mesenchymal cells form a reservoir that pro-
motes cancer recurrence, and EMT regulators are important
targets for anticancer therapy. Proteomics analysis has iden-
tified signatures of epithelial and mesenchymal pathways in
NSCLC lines, and a mesenchymal phenotype lacking cell
polarity defines a loss of cell sensitivity to EGFR TKIs. This
has led to measuring EMT in patient samples by differential
expression of ECAD and vimentin. Patients with low expres-
sion levels of ECAD by fluorescence IHC (N 216) tumors
have low survival rates. These data support the use of EGFR
in preclinical models, which works in tumor cells with a
functional EGFR –ERB3-Akt signaling axis working in epi-
thelial-phenotype tumor cells. The combination of EGFR
TKI inhibitor and an mTor inhibitor is additive in the epithe-
lial cell phenotype but synergistic in tumor cells with consti-
tutive activation of Akt in the presence of inhibition of EGFR
autophosphorylation. The key is to find new drug targets in
NSCLC that are not responsive to EGFR inhibition, particu-
larly if they target what is driving the mesenchymal state.
Pan Erb and Irreversible Inhibitors
Bruce Johnson, MD, reported that the irreversible pan
erbB receptor TKI HKI-272 has activity in Phase I trials in
breast cancer. A randomized phase II trial of HKI-272 is
being conducted in NSCLC with and without EGFR muta-
tions that have progressed on gefitinib or erlotinib and have
also been studied in preclinical lung cancer line models.
Nasser Hanna, MD, reported that the irreversible pan
Erb inhibitor BIBW2292 provides dual EGFR and Her2
inhibition. This includes working in NSCLC with EGFR
T790M mutations. A phase I monotherapy trial with 145
treated patients (2 partial responses and 56 stable disease) has
been conducted along with a BIBW2992  docetaxel trial
with 44 patients (4 objective responses and 13 stable disease).
Tom Lynch, MD, reported that the pan HER TKI
(PF-00299804, Pfizer) is a potent, irreversible inhibitor of
(Her) ERB1, 2, 3, and 4. It is orally available as a small
molecule. Many solid tumors are driven by several proteins in
the HER pathways and this has improved pharmacology. The
drug is in phase I trials (NKI, Colorado, UCLA, Dana
Farber), and phase II trials are planned later in 2007. This
drug is effective in HCC827 (EGFR-mutant) NSCLC cells
that have been selected to have a T790M resistance mutation
in xenograft models.
Heather Wakelee, MD, reported that XL647 inhibits
multiple receptor tyrosine kinases (EGFR, HER2, VEGFR2,
EPHB4) and has been studied in phase I trials (41 patients, 12
NSCLCs). Fourteen cases of stable disease and 1 partial
response were seen, as were a variety of adverse events
(particularly diarrhea, rash, nausea, and fatigue). A phase II
trial with XL647 (350 mg/p.o qd 5/14 days) as first-line
therapy in stage IIB or IV NSCLC is being conducted with
patients who have EGFR-activating mutation or at least two
of the following features: Asian ethnicty, female sex, minimal
smoker status, and adenocarcinoma histology. Also there is
an ongoing phase I trial of continuous dosing using plasma
for analysis and eyebrow hair bulbs as surrogate tissue of
analysis of activity of AKT and ERK by IHC.
New Trial Designs for Targeted Therapy
J. Jack Lee, PhD, reported that adaptive randomization
designs for targeted therapy, which incorporate biomarkers,
are particularly suitable for early stage drug development.
This was present in the context of the MDACC “BATTLE”
Trial (Biomarker-based Approaches of Targeted Therapy for
Lung Cancer Elimination). This statement is particularly true
for identifying high-risk subjects, identifying subpopulations
most likely to benefit from the treatment, selecting effective
treatment and dropping ineffective treatment early, and thus
providing a more ethical design for study. These new trial
designs allow the correct conclusion to be reached sooner and
allow flexibility in study conduct. The designs aid in identi-
fying important predictive biomarkers for treatment and pro-
vide a large tissue database for future biomarker discovery.
Predictive Tests for Chemotherapy Sensitivity –
Ramaswamy Govindan, MD
DNA repair is a critical process that enables cells to
identify and repair damaged DNA molecules, thus protecting
them from premature death or mutations. Cells exposed
continuously to the onslaught of environmental and metabolic
insults regularly sustain injury to DNA. Multiple cellular
mechanisms have evolved over time to repair the broken,
damaged DNA to avoid cell death and, more importantly,
disease-causing mutations. It is estimated that approximately
130 genes and their products are involved in the DNA repair
processes. It has been known for quite some time that defects
in the DNA repair pathway lead to premature ageing, mental
retardation, and heightened susceptibility to carcinogenesis–
all resulting from the inability of cells to repair DNA damage
efficiently.
The ability of cancer cells to survive DNA damage
inflicted by platinum compounds depends to a great extent on
the efficiency of the DNA repair process. Platinum com-
pounds damage cells by binding to DNA and forming DNA-
platinum adducts, resulting in activation of the DNA repair
pathways. Cells, both normal and malignant, differ signifi-
cantly in their ability to carry out this all-important repair
process. A brief overview of the cellular response to DNA
damage would help us understand how best to exploit the
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weakness in the system and identify those patients who would
benefit from DNA-damaging agents such as platinum com-
pounds.
DNA Damage Repair Pathway
DNA damage alters the configuration of the double helix
and is immediately detected by cells. Appropriate DNA repair
enzymes are recruited depending on the type of DNA damage.
Broadly speaking, there are four types of DNA damage.
1. Covalent modifications of the 4 bases in DNA (A, T, C, G).
2. Mismatches of normal bases because of errors in proof-
reading during DNA replication.
3. Crosslinks between bases.
4. Single-strand or double-strand breaks.
Damaged bases are repaired by direct chemical reversal
or by excision repair. Chemical reversal is a rather inefficient
process: multiple different proteins are required for correction
of several possible types of chemical alteration of bases. In
contrast, excision repair is a very efficient process and is able
to repair a wide variety of damages to the bases with a limited
set of enzymes. The three modes of excision repair are base
excision repair, nucleotide excision repair (NER), and mis-
match repair.
Base excision repair involves removal of the damaged
base, removal of its deoxyribose phosphate, replacement with
the correct nucleotide, and finally ligation of the breaks in the
strand. Several genes are involved in this process. NER
involves the removal of a nucleotide even if only one base is
damaged. NER begins with recognition of the damaged site
and follows with unwinding of the DNA using the enzyme
system transcription factor IIH and removal of the damaged
portion, which is filled in with a freshly synthesized DNA
fragment. DNA polymerases and DNA ligase play a crucial
role in accomplishing this process. Xeroderma pigmentosum
(XP) is a disease caused by mutation in one of several genes
in the NER pathway (XPA, XPB, XPD, XPF and XPG).
The mismatch repair pathway involves correcting the
mismatched bases of the normal bases. This process ensures
normal base pairing and is accomplished by recruiting en-
zymes involved in base excision repair and NER and some
unique enzymes. These unique enzymes recognize the mis-
match (MSH2) and delete the mismatched bases (MLH1).
Synthesis of the correct bases involves the use of enzymes in
the NER pathway.
This brief overview will focus on two members of the
DNA pathway and their ability to predict response to chemo-
therapeutic agents. Moreover, they may be of importance in
predicting outcomes after surgery as well.
ERCC1 (Excision Repair Cross-Complementation
Group 1)
Platinum compounds bind covalently to genomic DNA,
forming adducts. These adducts alter DNA, resulting in
recruitment of the DNA repair pathway enzymes mentioned
above. Cisplatin-induced DNA damage is repaired by the
NER pathway. ERCC1 is one of 16 genes that are involved in
the NER pathway. ERCC1 heterodimerizes with XPF, result-
ing in 5excision of the DNA strand. ERCC1 is essential for
life. In vitro studies indicate that ERCC1 is perhaps the most
important enzyme in the NER pathway. Polymorphisms in
the ERCC1 gene and the presence of multiple variants of
alternative splicing modify the expression of ERCC1 protein.
Regulatory Subunit of Ribonucleotide
Reductase (RRM1)
The RRM1 gene, which codes for the regulatory sub-
unit of ribonucleotide reductase, is located on 11p15.5. Loss
of heterozygosity of this region has been well described for
lung cancer. Ribonucleotide reductase plays a key role in the
synthesis of deoxyribonucleotides from the corresponding
ribonucleotides, thus providing the essential building blocks
necessary for NER. Preclinical studies suggest that high
RRM1 expression is associated with decreased cell prolifer-
ation, reduced invasiveness, and lower metastatic potential.
Moreover, RRM1 is an important determinant of the efficacy
of the nucleoside analog gemcitabine.
Predictive Utility of ERCC 1 or RRM1
Expression in Tumor Tissue
Predictive Value of ERCC 1 for Response to
Platinum-Based Therapy
Several studies have correlated ERCC1 expression in
NSCLC tumor tissue or ERCC1 germline polymorphisms
with response to platinum-based combination chemotherapy.
Tumors that are positive for ERCC1 survive platinum-in-
duced cell damage because they have a more efficient DNA
repair system than tumors that are negative for ERCC1.
Therefore, patients with high ERCC1 expression in their
tumors are less likely to benefit from platinum-based therapy
than are patients whose tumors have high ERCC1 levels.
The International Adjuvant Lung Cancer Trial (IALT)
study reported improved survival for patients with low tumor
levels of ERCC 1 when treated with adjuvant chemotherapy.
The IALT study randomly allocated 1867 patients with re-
sected stage I-III NSCLC to cisplatin-based chemotherapy or
observation. This study demonstrated a 4.1% absolute im-
provement in 5-year survival after chemotherapy compared
with observation alone. Of 761 tumors available, 335 (44%)
were positive for ERCC1 by immunohistochemical analysis.
Cisplatin-based adjuvant chemotherapy improved survival in
patients with ERCC1-negative tumors (adjusted hazards ratio
for death 0.65; 95% confidence interval [CI], 0.50–0.86, p 
0.002) compared with observation alone. No improvement in
survival was observed with adjuvant platinum-based chemo-
therapy in the ERCC1-positive group (adjusted hazards ratio
for death 1.14; 95% CI, 0.84–1.55; p 0.40). Several studies
have reported correlation between improved survival with
platinum-based chemotherapy and low tumor ERCC1 levels
in patients with advanced NSCLC (Table 1). In a retrospec-
tive study of 54 patients with limited-stage SCLC presented
at this conference, low levels of ERCC1 were associated with
better survival when treated with platinum-based chemora-
diation.
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Predictive Value of RRM1 for Response to
Gemcitabine-Based Therapy
In a small retrospective study of 61 patients with
advanced NSCLC treated with cisplatin and gemcitabine, low
RRM1 levels were associated with a trend toward improved
median survival compared with high RRMI mRNA levels
(13.9 versus 10.9 months; p  0.22). Similar results were
observed in the group with concomitant low expression levels
of ERCC1 and RRM1. Although the results are intriguing, no
definite conclusions could be drawn from this small retro-
spective study. Until recently, technical limitations precluded
immunohistochemical evaluation of RRM1 protein in paraf-
fin-embedded tissue specimens.
Prognostic Value of ERCC 1 or RRM1
Expression in Tumor Tissue
Prognostic Value of ERCC 1
Among the group of patients who did not receive
adjuvant chemotherapy in the IALT study, the survival was
better for those with ERCC1-positive tumors than for those
with ERCC1-negative tumors (adjusted hazards ratio for
death: 0.66; 95% CI: 0.49–0.90; p  0.009).
Prognostic Value of RRM1
In a retrospective study of patients with resected stage
I NSCLC, the median disease-free survival was significantly
better in the group with high RRM1 protein expression (more
than 10 years) than in those with low RRM1 expression (4.5
years; hazards ratio for disease progression or death, 0.46;
p  0.004). It is conceivable that efficient DNA repair
(associated with high RRM1levels) could slow down or
prevent molecular events related to progression even in al-
ready established tumors and thus contribute to better sur-
vival in patients with resected NSCLC. In fact, the combina-
tion of high RRM1 and high ERCC1 (a third of patients in
one study) predicted better survival than did high expression
of either protein alone in that study.
Prospective Study Tailoring Chemotherapy
Based on ERCC1 and RRM1 Expression
In a prospective study (“MADe IT”) presented at this
conference, the investigators from H.L. Moffitt Cancer Cen-
ter assigned 53 patients with advanced NSCLC to platinum-
or nonplatinum-based therapy on the basis of tumor ERCC1
expression: those with low ERCC1 received a platinum
(carboplatin)-containing doublet and those with high ERCC1
received a nonplatinum-containing doublet. The choice of the
second agent in the platinum-containing doublet group was
based on tumor RRM1 expression. Patients with low RRM1
expression received carboplatin and gemcitabine, and those
with high RRM1 expression received docetaxel and carbo-
platin. Similarly, patients assigned to nonplatinum-containing
doublet received either gemcitabine and docetaxel (low
RRM1 group) or docetaxel and vinorelbine (high RRM1
group). The overall 1-year progression-free survival was 18%
(95% CI: 7–33%) and the 1-year overall survival was 62%
(95% CI: 43–77%). The median overall survival was 13.4
months, which was better than the traditional 9 to 10 months
commonly reported with platinum-based doublet therapy.
Future Directions
The unfolding story of variation in the levels of key
enzymes in DNA repair pathway in established malignancies
has significant implications in the treatment of cancer. The
prognostic and predictive ability of some of the key enzymes
of DNA repair pathway would impact not only the approach
to lung cancer but also our approach to a wide variety of other
cancer types. Moreover, the preliminary data indicate that
expression levels of some of these key enzymes in resected
tumors may identify patients who are less likely to relapse. Of
course, further studies in larger samples are mandatory before
these tests could be used in the clinic. These innovative
studies have opened a new avenue for further research to
examine more closely the DNA repair pathway in established
cancer. Targeting chemotherapy to the right patient is no
longer a dream but a reality.
Novel Drugs – Jack West
Epothilones are a new class of anticancer drugs that
bind to and stabilize microtubules in a manner similar but not
identical to that of the taxanes, and several epothilones have
been developed and are in clinical trials. BMS 247550 is an
epothilone B analog that has been studied in two different
schedules in phase II trials of previously treated patients with
advanced NSCLC, as both a single q21 day dose of 32 mg/m2
(N  77) and a day 1–5 dose of 6 mg/m2 q21 days (N  69).
Each of these regimens has demonstrated a response rate in
the 10 to 15% range and a median survival of 7–8 months.
Epothilone D, or KOS-862, has also been evaluated in a
phase II trial of 100 mg/m2 q21 days in previously treated
patients with advanced NSCLC (N  55), in which a single
response was observed. Other epothilones are still in phase I
TABLE 1. ERCC1 Expression-Predicting Response to Chemotherapy
Author N Stage Type of Chemotherapy ERCC1 Level Median Survival p Response CR&PR p
Olaussen et al. 389 I–III Cis-Vinorelbine Low
High
56 (mo)
50 (mo)
0.34 NA NA
Lord et al. 56 IIIB–IV Cis-Gemcitabine Low
High
62 (wk)
20 (wk)
0.009 52%
36.4%
0.38
Ceppi et al. 61 III–IV Cis-Gemcitabine Low
High
17.3 (mo)
10.9 (mo)
0.0032 NA NA
Rosell et al. 160 IV Cis-Gemcitabine Low
High
18.3 (mo)
NR
56.6%
37.7%
0.02
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studies. Despite hints of activity across a range of tumor types
and challenging toxicities, epothilones have all demonstrated
problematic myelotoxicity and neuropathy. They continue to
have no clear role despite years of development, leaving
questions about whether these agents will ever demonstrate
an adequate therapeutic index for clinical use.
BMS-275183 is an oral taxane similar in structure to
paclitaxel that has undergone phase I investigation in a range
of solid tumors on a weekly schedule and then on a twice
weekly schedule. These studies have demonstrated that the
dose-limiting toxicities (DLTs) are neurotoxicity and, to a
lesser extent, diarrhea and fatigue on a weekly schedule,
while the twice weekly schedule had DLTs of neutropenia
and diarrhea and comparably less neuropathy. With 14 re-
sponses among 73 patients between the 2 trials, including 7
partial responses among 26 patients with NSCLC and evalu-
able disease, this agent was felt to be quite encouraging, and
the twice weekly schedule was selected for phase II study due
to the lower incidence and severity of neurotoxicity. Never-
theless, in subsequent phase II work with BMS-275183 in
patients with previously treated advanced NSCLC, excessive
and unpredictable toxicity from febrile neutropenia was seen.
The development of this agent is currently on hold.
In its IV form, the topoisomerase I inhibitor topotecan
is an FDA-approved drug in the setting of recurrent SCLC,
but oral topotecan has also been the subject of clinical trials
in this setting. In an important phase III trial comparing oral
topotecan 2.3 mg/m2 days 1–5 of a 21-day cycle with best
supportive care to best supportive care alone in the second-
line setting for 141 SCLC patients, a significant survival
benefit was observed (hazard ratio: 0.64). This oral regimen
has also been compared in a phase III trial with IV topotecan
at the approved dose and schedule of 1.5 mg/m2 on days 1–5
of a 21-day schedule and was found to have equivalent
efficacy in terms of response and survival in the second-line
SCLC setting. Finally, oral topotecan combined with IV
cisplatin has been compared in a phase III trial to standard
cisplatin and etoposide, both administered every 3 weeks for
up to 4 cycles or 2 cycles beyond best response in the setting
of first-line extensive disease SCLC. This study, with nearly
800 enrolled patients, demonstrated a nearly identical median
survival and overall efficacy. Oral topotecan is not yet com-
mercially available but is awaiting FDA review.
Nanoparticle albumin bound (nab) paclitaxel, the novel
formulation that does not require Cremaphor or steroid pre-
medication, can be administered as a 20-minute infusion
without the risk of solvent-based hypersensitivities. Ap-
proved by the FDA in 2005 for the treatment of recurrent or
metastatic breast cancer, nab paclitaxel has also been studied
in first-line treatment of advanced NSCLC. As a single agent
administered at 260 mg/m2 IV every 3 weeks in 43 patients,
it has been shown to produce a response rate of 16%, 33% of
patients with stable disease for 4 months or longer, a median
progression-free survival and a median overall survival of
11.6 months, and toxicity limited to grade 4 or lower. It has
also been studied at a weekly dose of 125 mg/m2 weekly for
3 of 4 weeks, with a response rate of 30%, 23% with stable
disease, and a median survival of 11 months among 40
previously untreated patients. It is the weekly approach that is
being studied in combination with carboplatin, with a re-
sponse rate of 50% and 36% demonstrating stable disease.
Among the 50 enrolled patients, 44% had grade 3 or 4
neutropenia, but there was serious neuropathy. A phase III
trial is planned in which a combination of weekly nab
paclitaxel and q3week carboplatin will be compared with
standard CP in 100 or more previously untreated patients with
advanced NSCLC for patients who cannot receive bevaci-
zumab due to ineligibility of unavailability.
Paclitaxel poliglumex (PPX) is another novel formula-
tion of paclitaxel in which the taxane is bound to a biodegrade-
able polymer using a polyglutamate drug delivery system, al-
lowing administration without solvents over a recommended
infusion time of 10 to 20 minutes and potentially allowing for
improved delivery of the agent to the tumor target with
relative sparing of normal tissues. PPX has already been
studied in several phase III randomized trials in the perfor-
mance status 2 (PS2) patient population. In the STELLAR 3
trial, the combination of carboplatin/PPX was compared with
CP q3weeks, while the STELLAR 4 trial compared single-
agent PPX to gemcitabine or vinorelbine as a single agent.
Each of these first-line trials demonstrated no significant
overall differences in survival or other efficacy end points
between the two trials, but an exploratory analysis of the
female patients in both of these trials revealed a markedly
superior survival in recipients of PPX. Subsequent careful
assessment for a potential explanation for this gender-based
difference may find that the release of the paclitaxel molecule
from the polymer backbone of PPX requires intracellular
cleavage by lysosomal proteases, particularly cathepsin B,
which is up-regulated by estrogen. On the basis of these
results, a follow-up randomized phase III trial of women with
PS2, known as PIONEER, was initiated to compare PPX with
solvent-bound paclitaxel. This trial was discontinued re-
cently. A follow-up trial is being initiated that will compare
carboplatin  PPX versus CP in premenopausal women with
PS 2.
Novel Inhibitors of Mitosis
Aurora kinases are involved in the normal mitotic
process, and mutations of these proteins are associated with
disruption of cell division. Because these proteins are in-
volved with the polar regions of the cell during mitosis, it was
named Aurora after the aurora borealis, or northern lights.
Aurora kinases are strongly overexpressed in more than 40
NSCLC tumors tested, and overexpression in lung tumors has
been associated with worse survival. There are several aurora
kinase inhibitors (all IV drugs,) that have been developed and
are now in or about to enter clinical trials. Those latest in
development include MK-0457 (Merck), AZD1152 (Astra-
Zeneca), and PHA-739385 (Nerviano). Pololike kinase inhib-
itors are just entering clinical trials and appears to have
neutropenia as the most frequent DLT. Thus far, early clinical
research indicates that neutropenia is the DLT for all of these.
Clinical development of several of these agents in lung cancer
trials is ongoing.
Bortezomib is a proteosome inhibitor that stabilizes cell
cycle regulatory proteins and can have a wide range of
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anticancer mechanisms, including antiangiogenic activity and
induction of apoptosis. Davies and colleagues presented the
results of a phase II SWOG trial of the combination of
bortezomib 1.0 mg/m2 IV days 1, 4, 8, and 11 with carbo-
platin  gemcitabine on a q21 days schedule in the first-line
treatment of NSCLC, which led to an 11-month survival and
1-year survival of 47%. Based on emerging work out of UC
Davis suggesting that sequencing bortezomib after docetaxel
can enhance the apoptosis of cancer cells, a subsequent
randomized phase II trial will randomly allocate patients with
advanced NSCLC to second-line docetaxel at 75 mg/m2 IV
along with bortezomib administered concurrently at 1.6
mg/m2 on days 1 and 8, or sequentially on days 2 and 9, every
3 weeks. Another randomized phase II trial of erlotinib alone
versus erlotinib  bortezomib on the days 1 and 8 q21 day
scheduled has finished accrual and awaits further follow-up
and presentation. Another phase II trial that has also com-
pleted accrual but has not yet been presented randomly
allocated patients in the second-line setting to bortezomib,
pemetrexed, or a combination of the two. Finally, bortezomib
is also being studied in advanced NSCLC.
Pralatrexate (PDX), a novel antifolate, is a chemically
modified derivative of methotrexate rationally designed to
optimize intracellular concentrations and accumulation. Pre-
clinical studies have demonstrated dramatic antitumor activ-
ity in lung and breast cancer xenograft models. A phase I
study in patients with extensively pretreated advanced
NSCLC (N  33) evaluated a weekly as well as a q2 week
dosing schedule and identified an optimal phase II dose and
schedule of 150 mg/m2 q 2weeks in the absence of B12 and
folate supplementation. The DLT was stomatitis, and there
was no significant myelosuppression. Two partial responses
were seen among patients with NSCLC. Subsequent devel-
opment of PDX with B12 and folate supplementation have
allowed for dose escalation as a single agent to doses twice
that possible without supplementation. PDX is being studied
further as a single agent and in combination with docetaxel or
paclitaxel. There is potential for development of phase III
trials comparing PDX to one or more currently available
second- and third-line treatment options in advanced NSCLC.
Vinflunine is a rationally designed microtubule inhibi-
tor that has demonstrated antitumor activity against a wide
range of human tumor xenografts and additivity or synergy
with multiple currently used chemotherapeutic agents. Vin-
flunine is freely soluble in water, allowing for IV adminis-
tration without Cremaphor or polysorbate 80 as solvents, no
need for steroid premedication, and a short infusion time of
10–20 minutes. Clinical studies that have focused on a dose
and schedule of 320 mg/m2 IV q21 days have thus far
demonstrated myelosuppression, fatigue, and constipation as
the leading adverse effects. A phase II trial at this dose in the
second-line setting for NSCLC demonstrated an 8% RR and
a 50% SD rate among 60 patients, with a median duration of
response of 5.8 months and a median OS of 7 months. These
results have been considered promising enough to pursue a
randomized phase III trial of vinflunine 320 mg/m2 IV q21
days versus docetaxel 75 mg/m2 IV q21days as second-line
therapy, which accrued 551 patients before enrollment was
closed in 2005. In addition, vinflunine is being studied in
trials combining it with multiple agents in the first-line and
second-line settings as well as concurrently with radiation.
Novel Targets
John Minna, Giorgio V. Scagliotti
The growing knowledge about altered molecular mech-
anisms in cancer cells is driving the discovery of potential
novel agents against new cellular targets which can act alone
or in combination with cytotoxic chemotherapy or other
targeted agents to ultimately improve cancer control. Several
of these novel targets have implications for treating lung
cancer stem cells or the niche they reside in (these include
Notch pathway inhibitors, semaphorin replacement, Hedge-
hog pathway targets, and agents targeting telomerase). Other
novel agents target the metabolism of oncogene products, key
signaling pathways for growth factors, and related pathways.
Heat Shock Protein Inhibitors. Heat shock protein-90
(Hsp-90) is a chaperone protein responsible for the proper
folding and function of several “client” oncogenic proteins,
including bcr-abl, c-kit, EGFR, Her-2, Flt-3, VEGFR/HIF-
1, and p-Akt. Consequently, the inhibition of Hsp-90 rep-
resents an alternative possibility to inhibit in cancer cells the
activity of these proteins. IPI-504 is a potent and selective
inhibitor of Hsp-90. It is administered in a 30-minute IV
infusion and is currently in phase I-II clinical testing. IPI-504
could represent a therapeutic alternative for those NSCLC
cells harboring a secondary EGFR mutation (T790M muta-
tion) but which are still dependent on Hsp-90 function.
Notch Pathway Inhibitors. Notch was discovered more
than 80 years ago in Drosophila when haploid insufficiency
resulted in “notches” at wing margins. In mammals, Notch is
important for the proper development in many organs (lym-
phogenesis, neurogenesis, and hair/sensory development).
Notch is also crucial for vascular development and in normal
adults, Notch expression is reduced to vascular systems. High
expression levels of Notch1–3, Jagged1, and Hes1 can be
detected in resected lung cancers or lung cancer cell lines,
and activated Notch3 in developing lung inhibits terminal
differentiation and induces hyperplasia of immature pneumo-
cytes. Notch3 cooperates with the EGF pathway in maintain-
ing the malignant phenotype, while inhibition of Notch3
activation in vitro induces apoptosis and results in loss of
malignant phenotype. Preliminary data indicate that inhibit-
ing Notch by using the -secretase inhibitor MRK003 re-
duces tumor growth in vivo. The cross-talk between Notch3
and the EGF pathway also suggests that inhibiting Notch3
may enhance tumor sensitivity to an EGFR TKI.
Semaphorins as Novel Therapeutics. SEMA3F is one
of 2 secreted semaphorins (SEMA3B and SEMA3F) residing
in the 3p21.3 tumor suppressor gene region. Their expression
is inactivated in most lung cancers and in other common
human tumors, such as breast cancer. SEMA3F binds to
neuropilin receptors and thus can antagonize the function of
VEGF, which also binds to these receptors. SEMA3F expres-
sion is lost in lung cancer, and replacing SEMA3F results in
reversal of much of the invasive malignant phenotype. Thus,
SEMA3F and SEMA3B as soluble molecules (or small mol-
ecule mimics) are candidates for development as new targeted
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therapeutic agents to replace this function lost in lung cancer
cells. Because of their role in counteracting VEGF, they may
play a special role in VEGF-targeted therapy as well.
Insulin-Like Growth Factor (IGF) Signaling Pathway
Inhibitors. Increased IGF levels and higher expression of
IGF-1R have been found in cancer patients. IGF-IR is in-
volved in cellular transformation and mediates tumor survival
and growth. In addition, human tumors produce IGF-II as an
autocrine growth factor. BIIB22 is a high-affinity, fully hu-
man IgG4 nonglycosylated antibody that blocks the interac-
tion of IGF-I and IGF-II with IGF-IR, inhibits downstream
signaling (pIGF-IR, pAkt, pErk), and down-regulates IGF-IR
cell surface expression. BIIB22 inhibits IGF-I and IGF-II-
mediated growth of tumor cell lines and in vivo tumor
growth. IMCA12 is a fully human IgG1 monoclonal antibody
with high-affinity binding to human IGF-IR and no affinity
for the human insulin receptor. It inhibits IGF-I and IGF-II
binding to IGF-IR, inhibits IGF-IR phosphorylation, and
promotes IGF-IR degradation. Antitumor activity has been
shown in xenograft and orthotopic models when administered
alone, in combination with chemotherapeutic agents, and in
combination with cetuximab. In phase I studies it has been
administered in weekly, every 2 weeks, and every 3 weeks
schedules. CP-751,871 is a fully human IgG2 monoclonal
antibody against IGF-IR and, similar to IMCA12, does not
bind to the insulin receptor and induces IGF-IR internaliza-
tion and degradation. Currently, no DLT has been identified
for IGF alone or with chemotherapy when given up to 10
mg/kg. An ongoing phase II randomized study (2:1 random-
ization) of CP / CP 751,871 has response rate as a
primary end point.
Hedgehog Pathway Inhibitors. Like the Notch and Wnt
pathways, the Hedgehog signaling pathway is important in
embryonic development, including lung development. The
Hedgehog pathway is especially important in neuroendocrine
lung development and in SCLC. These tumors depend on
ligand dependent activation. Cyclopamine, an antagonist of
one component of the Hedgehog pathway, smoothened,
has preclinical activity against SCLC. Other smoothened
antagonists can be developed. Likewise, antibodies against
the ligand Hedgehog are candidate novel therapeutics
directly analogous to monoclonal antibodies directed
against VEGF, which are known to be successful in the
treatment of lung cancer. The Hedgehog pathway will
probably be important in the maintenance of lung cancer
stem cells. Thus, therapy directed against this pathway will
likely target tumor stem cells.
Telomerase Inhibitors. Telomerase activity is activated
in perhaps all lung cancers of all histologic types. This
enzyme and its RNA cofactor are absolutely required for the
immortal growth of tumor cells and the maintenance of
telomere ends of chromosomes. While normal stem cells in
the body also express telomerase, preclinical studies have
shown that there is a large therapeutic window for telomerase
to be inhibited in tumor cells without harming the organism
as a whole. The telomerase RNA component inhibitor
GRN153L has been developed and is effective in telomerase
inhibition. Extensive preclinical studies have demonstrated
its significant activity against lung cancer xenografts. It has
entered phase I clinical trials, and phase II trials in lung
cancer are being designed. The key for its development is to
integrate it with standard chemotherapy. Preclinical lung
cancer xenograft models show that this is possible.
Src Inhibitors. C-src is a cytoplasmic nonreceptor ty-
rosine kinase family that links signaling from growth factor,
integrin, and cytokine receptors on the surface of cells to their
downstream effector signaling cascades, such as PI3K/PTEN/
Akt, Stats, Ras/Raf/ERK, and focal adhesion kinase. Regu-
lation of these key pathways allows SRC to control cellular
growth and proliferation, survival, invasion and metastasis,
and angiogenesis. In lung cancer, c-Src can cooperate with
EGFR and src activity can be required for transformation by
EGFR. Currently C-Src TKIs entering in clinical programs
include dasatinib (which inhibits also abl, EPHA2, PDGF-R
and c-kit), AZD-0530, and SKI-606. The effect of dasatinib
on NSCLC cells is cell line dependent and includes cell cycle
arrest, apoptosis, and reduced cellular invasion. In cell lines
EGFR status or dependency is predictive: EGFR mutant cells
undergo apoptosis, while EGFR wild-type cells are depen-
dent on EGFR for proliferation undergo G1 arrest. The
association of dasatinib and erlotinib results in synergistic
inhibition of cellular proliferation in cell lines responsive to
EGFR TKI. In Phase I studies with dasatinib, main toxicities
included gastrointestinal toxicity, fatigue, and rash.
A phase I/II study testing the safety and tolerability of
erlotinib dasatinib in previously treated NSCLC in patients
with good performance status and without previous exposure
to EGFR TKI is already planned. AZD 0530 has been tested
in a phase I study in solid tumors with doses ranging from 60
to 250 mg/d p.o. for 14 days. DLTs included febrile neutro-
penia and fatigue, and the maximum tolerated dose was 175
mg/d. Phase II studies have been planned or initiated for
NSCLC, prostate cancer, melanoma, colorectal cancer, and
pancreatic cancer.
Novel Targets 2
Steven Dubinett
Histone deacetylase inhibitors increase histone acetyla-
tion, resulting in DNA with a more open chromatin, thus
favoring transcription. HDAC inhibitors such as suberoyla-
nilide hydroxamic acid (SAHA) have been found to inhibit
proliferation of NSCLC cells in preclinical studies. Thus,
reversible histone acetylation regulates gene expression, and
epigenetic modification has become an important target for
anticancer therapy. Previous preclinical studies provided ra-
tionales for combining HDAC inhibitors with CP. These
include the finding that SAHA can enhance the antitumor
efficacy of platinum compounds. The rationale for combina-
tion with the taxanes includes the fact that HDAC6 interacts
with beta-tubulin and alters microtubule dynamics; thus,
inhibition of HDAC6 leads to mitotic arrest. SAHA has also
been shown to lower the apoptotic threshold to other agents
by causing inhibition of Akt phosphorylation. Dr. Chandra
Belani presented new findings regarding a phase I study with
the HDAC inhibitor vorinostat (SAHA) in combination with
CP for patients with advanced solid malignancies. Of 19
patients with advanced NSCLC in this trial there were 10 PR
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and 4 patients with SD. On the basis of this study, SAHA 400
mg/d for 2 out of 3 weeks in combination with full doses of
CP was the recommended phase II dose. On the basis of these
results a randomized phase II study will enroll 80 stage
IIIb/IV patients with PS 0/1 and no prior chemotherapy. The
primary end point will be the response rate. The discussion
period also included mention of additional ongoing studies in
which SAHA is being combined with erlotinib. Here the
rationale includes the HDAC inhibitor-mediated up-regula-
tion of tumor E-cadherin expression, which may enhance the
efficacy of the EGFR TKI.
In related studies, Dr. Charles Rudin described a com-
bination therapy targeting epigenetic silencing by using ther-
apy with both HDAC inhibitors and demethylating agents.
The combination therapy is intended to target multiple epi-
genetic levels by concurrent targeting of promoter hyper-
methylation (using 5-azacytidine, a DNMT inhibitor) and
histone deacetylation (with MS-275, an HDAC inhibitor).
The overall goal of this approach is to induce a durable
reversal of gene silencing.
The mammalian target of rapamycin (mTOR) has
emerged as an important therapeutic target for cancer. Rapa-
mycin and its derivatives that specifically inhibit mTOR are
undergoing evaluation in clinical trials. Preclinical studies
indicate the mTOR inhibitors are active in lung cancer mod-
els, and increased efficacy has been demonstrated for the
combination of mTOR inhibitors with chemotherapy or
EGFR inhibitors. Early reports have indicated clinical re-
sponses to monotherapy with mTOR inhibitors. Dr. Fadlo
Khuri reviewed the rationale for the use of rapamycin in
combination therapies. He discussed the trial conducted by
Vince Miller in which the mTOR inhibitor RAD001 was used
with gefitinib. Preliminary results in the phase I trial indicated
2 PR out of 10 patients treated. These patients with PR were
male, were smokers, and had no EGFR mutations.
The rationale for combination therapies with arachi-
donic acid (AA) pathway inhibitors was discussed in two
presentations. The first presentation encompassed the work of
Dr. Martin Edelman, who found that COX-2 expression is a
positive predictive factor for celecoxib plus chemotherapy in
advanced NSCLC (CALGB 30203). The study was based on
the hypothesis that COX-2 or 5- LOX inhibition will enhance
the efficacy of platinum-based chemotherapy in advanced
NSCLC. The investigators sought to inhibit both pathways
because AA metabolites have been shown to regulate angio-
genesis, apoptosis resistance, and invasion and metastasis.
Patients with IIIb (pleural effusion) or IV NSCLC PS0-2
received (1) carboplatin (C) AUC  5.5, gemcitabine (G)
1000 mg/m2 and zileutin (Z) 600 mg po qid; (2) C  G 
celecoxib 400 mg po bid; or (3) C G Z celecoxib. End
points included PFS (9 months) and OS. The study failed to
achieve its predefined goal of a 9-month PFS 50%. In
correlative studies, IHC indicated that COX-2 is a negative
prognostic factor for survival but a positive predictive factor
for survival if patients received celecoxib. Multivariate anal-
ysis confirmed the interaction of COX-2 expression and
response to celecoxib. A phase III randomized trial testing the
hypothesis that COX-2 inhibition is beneficial in patients with
COX-2-overexpressing tumors is under discussion.
In a second presentation regarding combination therapy
targeting the AA pathway, Dr. Karen Reckamp described a
phase I trial combining erlotinib with celecoxib. Overexpres-
sion of COX-2 activates extracellular signal-regulated kinase/
mitogen-activated protein kinase signaling in an EGFR TKI-
resistant manner. Overexpression of tumor COX-2 also
suppresses E-cadherin expression in a prostaglanding E2-
dependent manner. This is important because low E-cadherin
expression has been associated with resistance to EGFR TKI.
Because preclinical data indicated that tumor COX-2 expres-
sion caused resistance to EGFR TKI, a phase I trial to
establish the optimal biologic dose (OBD), defined as the
maximal decrease in urinary prostaglandin E-M (PGE-M),
and the toxicity profile of the combination of celecoxib and
erlotinib in advanced NSCLC was performed. Twenty-two
subjects with stage IIIB/IV NSCLC received increasing doses
of celecoxib from 200 to 800 mg twice daily (bid) and a fixed
dose of erlotinib. Primary end points included evaluation of
toxicity and determination of the OBD of celecoxib combined
with erlotinib. Secondary end points investigated exploratory
biologic markers and clinical response. Twenty-two subjects
were enrolled, and 21 were evaluable for the determination of
OBD, toxicity, and response. Rash and skin-related effects
were the most commonly reported toxicities and occurred in
86% of patients. There were no DLTs and no cardiovascular
toxicities related to study treatment. All subjects were eval-
uated on intent to treat. Seven patients showed partial re-
sponses (33%), and five patients developed stable disease
(24%). Responses were seen in patients both with and with-
out EGFR-activating mutations. A significant decline in uri-
nary PGE-M was shown after 8 weeks of treatment, and the
OBD of celecoxib of 600 mg bid. This study defines the OBD
of celecoxib with a fixed dose of EGFR TKI. These results
show objective responses with an acceptable toxicity profile.
Future trials using COX-2 inhibition strategies should use the
OBD of celecoxib at 600 mg bid. A randomized phase II trial
in patients with advanced NSCLC comparing erlotinib plus
celecoxib to erlotinib plus placebo will begin this year.
Combinations of Radiation and Targeted Agents
Laurie Gaspar, Hak Choy
There are emerging data regarding the combination of
targeted agents and radiation therapy. Studies have been
performed, or are ongoing, of the combination of radiation
with EGFR inhibitors, antiangiogenic agents, and multitar-
geted agents such as pemetrexed and ZD6474.
Interest in EGFR inhibitors in combination with radia-
tion therapy has increased following the positive results of a
randomized phase III study of cetuximab and radiation versus
radiation alone in head and neck cancer (Bonner JA, et al.
NEJM 2006). Patients randomly allocated to receive cetux-
imab, a monoclonal antibody to the EGFR receptor, received
a loading dose in week 1 and then a weekly dose through
radiation. There was no chemotherapy in this study. The
median survival was 54 months for patients who received
cetuximab and 28 months in the control arm (p  0.02).
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RTOG 0324 was a phase II study of cetuximab with
chemoradiation in patients with stage III NSCLC. A week
after a loading dose of cetuximab, patients went on to receive
concurrent radiation with weekly cetuximab, paclitaxel, and
carboplatin. After completion of concurrent chemoradiation,
patients received 6 more weeks of weekly cetuximab with 2
cycles of CP given on a 3 weekly schedule. The study closed
in May 2005 having accrued 93 patients. Treatment was
reasonably tolerated: 9% of patients experiencing grade 4 or
5 toxicity, and 3 patients developed grade 4 or 5 pneumonitis.
Preliminary survival data indicate that the 1-year survival rate is
68%. RTOG is now planning a phase III study of chemoradia-
tion alone versus chemoradiation and concurrent cetuximab.
Other studies have looked at EGFR inhibition as main-
tenance therapy following standard chemoradiation for lo-
cally advanced NSCLC. SWOG 0023 was a randomized
phase III study for patients with unresectable stage III
NSCLC. Following registration, all patients received concur-
rent chemoradiation (cisplatin/vincristine/61 Gy) and then 3
cycles of docetaxel as consolidation. Patients were then
randomly allocated to maintenance therapy with gefitinib (an
EGFR TKI) or placebo. Patients were stratified by stage IIIA
versus IIIB, measurable versus nonmeasurable disease, and
squamous versus nonsquamous histology. This study was
closed early due to an interim analysis that showed that the
gefitinib arm could not have a median survival superior to
that of the placebo arm. The median survival was 19 months
for all patients entered on the study. There was no statistically
significant difference in the incidence of grade 3 or higher
pneumonitis observed between the two treatment arms.
There is also considerable interest in combining anti-
angiogenic agents with standard chemoradiation for stage III
NSCLC. Preclinical work has demonstrated increasing tumor
cell apoptosis with increasing doses of antiangiogenic agents
given with radiation therapy. SWOG 0533 is an ongoing phase
I trial integrating bevacizumab, an antiangiogenic agent, into the
treatment of locally advanced stage III NSCLC. All patients
receive concurrent cisplatin, etoposide, and 64.8 Gy thoracic
radiation therapy followed by 3 cycles of consolidation do-
cetaxel. With each new patient cohort, the bevacizumab is
moved earlier and earlier into the treatment regimen. Initially
bevacizumab is only given to patients after completion of
concurrent chemoradiation. Following successful enrollment
to this cohort, bevacizumab will begin day 15 of chemora-
diation. The final cohort will have bevacizumab starting day
1 of chemoradiation. Patients are placed into high- and
low-risk categories. High risk is defined as squamous cell
histology or tumor with cavitation or proximity to a major
vessel, or a history of hemoptysis greater than 1/2 tsp within
28 days of registration. The study looks at these 2 risk groups
separately. SWOG 0533 has an extensive correlative compo-
nent looking at serum and circulating endothelial cell and
tumor markers associated with hypoxia and angiogenesis.
Paracrine versus Perfusion Effects of Angiogenesis.
Drugs such as ZD6474 that have both antiepidermal growth
factor and antiangiogenic properties have been combined in
animal models and haven shown to have more activity than
radiation alone or radiation plus paclitaxel.
Pemetrexed is a multitargeted antimetabolite that has
shown activity in mesothelioma. Several studies are evaluat-
ing pemetrexed in NSCLC. Preclinical work has demon-
strated that it has additive or supra-additive effects when
combined with radiation therapy. A phase I study of escalat-
ing doses of pemetrexed and carboplatin have shown that the
2 drugs can be given in full dose (pemetrexed 500 mg/m2 and
carboplatin AUC 5 on a q 3 week schedule) with concurrent
thoracic radiation with a reasonable toxicity profile. There did
not appear to be any major enhancement of radiation pneu-
monitis or esophagitis. CALGB 30407 is a randomized phase
II study designed to test this combination of pemetrexed and
carboplatin with 70-Gy concurrent thoracic radiation in the
phase II setting. Patients receive either pemetrexed or carbo-
platin with thoracic radiation or the same regimen with the
addition of cetuximab. The regimen will be considered of
further interest if the median survival is 20.9 months or more.
Preliminary toxicity data has shown an increase in grade 3–4
thrombocytopenia and neutropenia in the cetuximab arm but
no increase in esophagitis or pneumonitis.
Another industry-sponsored phase I study is combining
pemetrexed with escalating doses of cisplatin, given concur-
rently with 74-Gy thoracic radiation. This will then be com-
pared in a randomized phase II design with the same regimen
but substituting carboplatin for cisplatin. Both arms receive 3
cycles pemetrexed. Numerous other phase I/II studies are
ongoing to look at pemetrexed in the combined modality
setting.
Apoptosis
D. Ross Camidge, Roy S. Herbst
Two main molecular pathways lead to effector caspase
activation and programmed cell death (apoptosis). The intrin-
sic pathway depends on the release of mitochondrial-derived
cytochrome C. The extrinsic pathway depends on the activa-
tion of cell-surface death receptors (Fas, TNF-receptor, or
TRAIL [TNF-related apoptosis inducing ligand] receptors).
Cytotoxic chemotherapy and radiotherapy are known to trig-
ger cell death predominantly through p53-dependent induc-
tion of the intrinsic apoptotic pathway, although considerable
cross-talk between the pathways exists. The down-regulation
of apoptosis in many cancer cells, through a variety of
different means, may underlie their resistance to standard
treatments, thus offering several targets for potential thera-
peutic intervention.
TRAIL Agonists (Ligand). TRAIL, or Apo2L, is a
naturally occurring 281-amino-acid secreted protein that
binds to both TRAIL-R1 and TRAIL-R2 (also called death
receptors 4 and 5 [DR4 and DR5], respectively) and triggers
apoptosis through the extrinsic pathway. Recombinant Apo2L,
which is a soluble zinc-coordinated homotrimer, has been
codeveloped by Genentech and Amgen and preclinically
appears to selectively induce apoptosis in cancer cells while
sparing the majority of normal cells (with the notable excep-
tion of hepatocytes). Surface expression of 3 other “decoy”
receptors (TRAIL-R3, TRAIL-R4, and TRAIL-R5 [Osteo-
protegerin]), which also bind TRAIL, may be one protection
mechanism used by the normal cells. Preclinically, the great-
est effects in Colo205 colon cancer xenografts were seen
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when Apo2L was combined with a traditional cytotoxic in the
form of CPT-11. A phase I all-comers dose-escalation study
of Apo2L given IV daily on D1–5 on a 21 day schedule to
patients with and without liver metastases is ongoing. Apo2L
was well-tolerated to up to 15 mg/kg/d. The plasma half-life
was approximately 2 to 3 hours. The linear pharmacokinetics
over the dose range was tested, and there was no suggestion
that the presence of hepatic metastases or mild hepatic dys-
function affected exposures. One confirmed partial response,
in a patient with metastatic synovial chondrosarcoma, has
been noted to date.
TRAIL Agonists (Monoclonal Antibodies). Although
Apo2L targets both TRAIL-R1 and TRAIL-R2, its relatively
short plasma half-life, leading to an intensive regimen of
administration, and novel manufacture have helped to
drivethe exploration of other, better-established drug formats
for targeting death receptors. Several companies have devel-
oped agonistic monoclonal antibodies (mAb) directed against
TRAIL-R1 or TRAIL-R2. Mapatumumab (HGS-ETR1) is a
fully human agonistic mAb directed against TRAIL-R1. It
has single-agent activity in H460 NSCLC xenograft models,
and there is evidence of synergy in combination with both
carboplatin and docetaxel. Two separate phase I all-comers
single-agent dose-escalation studies have been completed.
HGS-ETR1 was well-tolerated up to 20 mg/kg administered
on day 1 of a 28 day schedule or 10 mg/kg on a 14 day
schedule. The plasma half-life was 16–17 days, which is
consistent with other mAbs, and no human antihuman anti-
body responses were detected. The best response in the
single-agent phase I studies was stable disease. Three sepa-
rate single-agent phase II studies have been completed at 10
mg/kg every 14 or 21 days (NSCLC, colorectal cancer, and
NHL). No responses were seen in either the NSCLC or
colorectal cancer studies, but one complete response and two
partial responses were noted in the 15 patients with follicular
lymphoma in the NHL study. Phase Ib combination studies
with full-dose CP and with full-dose gemcitabine and cispla-
tin in patients in whom these drugs would be considered
“appropriate treatment” are complete or near completion. No
evidence of PK interaction has been noted. Responses to date
in the NSCLC patients have been in the expected range for
the use of cytotoxic agents alone. Although these TRAIL
agonist approaches appear well-tolerated and there are early
hints of activity in certain rare tumors, the next challenge is
to determine what these tumors have in common to facilitate
preidentification of those most likely to respond to death
receptor stimulation alone or in combination with standard
therapies.
Survivin Antisense. Survivin is an intracellular protein
that acts as a negative regulator of effector caspase activity
and has an as yet incompletely understood role in the phys-
iology of many normal cells. By both immunohistochemical
and transcriptional analysis, survivin is overexpressed in a
wide range of malignancies but appears absent from adjacent
normal tissues. Its expression in tumors correlates with
poorer prognosis, increased recurrence rates, and increased
resistance to therapy in NSCLC and head and neck cancer.
LY2181308 is an 18-mer antisense oligonucleotide that is
nuclease resistant and highly potent preclinically in down-
regulating surviving expression. It shows single-agent pre-
clinical activity against xenografts. A single-agent all-comers
phase I study of IV LY2181308 is ongoing. Toxicities to date
include transient clotting abnormalities, reversible comple-
ment activation, and mild flu-like symptoms during the infu-
sion. No activity signals have yet been detected, but phase II
studies are planned. There is interest from preclinical data in
combinations of LY2181308 with radiotherapy in NSCLC.
Peroxisome Proliferator-Activated Receptor- (PPAR-)
Agonists. PPAR- is a nuclear receptor that dimerizes with the
retinoid X receptor to influence transcription that promotes
differentiation (E-cadherin expression) and inhibit the growth of
NSCLC cell lines and xenografts. PPAR- is intimately associ-
ated with the Wnt7-a/Fzd9 pathway. Wnt7-a expression is lost in
some lung adenocarcinomas, and preclinically, restoration of
Wnt7-a expression reduces the soft-agar growth of cell lines
lacking Wnt7-a. Nonsteroidal anti-inflammatory drugs that re-
duce the development of new tumors in experimental models of
lung tumorigenesis act through PGI2-mediated PPAR- stimu-
lation. This stimulation, which is reproducible via the PGI2
agonist Iloprost, requires Fzd-9 expression. Randomized chemo-
prevention studies with Iloprost or placebo in smokers with
established bronchial dysplasia are ongoing.
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